Reference : NRAS mutant melanoma: Towards better therapies
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
http://hdl.handle.net/10993/47630
NRAS mutant melanoma: Towards better therapies
English
Randic, Tijana mailto [University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM) >]
Kozar, Ines mailto [University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM) >]
Margue, Christiane mailto [University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM) >]
Utikal, Jochen mailto [Skin Cancer Unit, German Cancer Research Center (DKFZ), D-69120 Heidelberg, Germany]
Kreis, Stephanie mailto [University of Luxembourg > Faculty of Science, Technology and Medicine (FSTM) > Department of Life Sciences and Medicine (DLSM) >]
29-May-2021
Cancer Treatment Reviews
W. B. Saunders Co.
99
Yes (verified by ORBilu)
0305-7372
1532-1967
London
United Kingdom
[en] cutaneous melanoma ; NRAS mutation ; MEKi/CDK4/6i dual therapy ; Resistance mechanisms ; New combination therapies
[en] Genetic alterations affecting RAS proteins are commonly found in human cancers. Roughly a fourth of melanoma patients carry activating NRAS mutations, rendering this malignancy particularly challenging to treat. Although the development of targeted as well as immunotherapies led to a substantial improvement in the overall survival of non-NRASmut melanoma patients (e.g. BRAFmut), patients with NRASmut melanomas have an overall poorer prognosis due to the high aggressiveness of RASmut tumors, lack of efficient targeted therapies or rapidly emerging resistance to existing treatments. Understanding how NRAS-driven melanomas develop therapy resistance by maintaining cell cycle progression and survival is crucial to develop more effective and specific treatments for this group of melanoma patients. In this review, we provide an updated summary of currently available therapeutic options for NRASmut melanoma patients with a focus on combined inhibition of MAPK signaling and CDK4/6-driven cell cycle progression and mechanisms of the inevitably developing resistance to these treatments. We conclude with an outlook on the most promising novel therapeutic approaches for melanoma patients with constitutively active NRAS.
Fonds National de la Recherche - FnR
http://hdl.handle.net/10993/47630
10.1016/j.ctrv.2021.102238
https://www.sciencedirect.com/science/article/pii/S0305737221000864?via%3Dihub

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Randic_et_al_2021_Review.pdfPublisher postprint3.26 MBView/Open

Bookmark and Share SFX Query

All documents in ORBilu are protected by a user license.